IN THE CLAIMS

Please amend the claims as follows:

Claim 1. (Original) Sodium trans-4-[1-[2,5-dichloro-4-[(1-methyl-1H-3-indolylcarbonyl)amino]phenylacetyl]-(4S)-methoxy(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylate pentahydrate.

Claim 2. (Original) A compound as described in claim 1, which is in the form of crystals.

Claim 3. (Original) A compound as described in claim 1 or 2, which is in the form of plate-like crystals.

Claim 4. (Currently Amended) A compound as described in any one of claims 1 to 3 claim 1, which is in the form of crystals having the full XRD pattern of FIG. 4characteristic peaks of angle of diffraction (20), as measured through powder x-ray diffractometry, at 7.2, 17.3, 18.9, 19.4, 20.4, and 21.6 (°).

Claim 5. (Original) A compound as described in claim 1 or 2, which is in the form of needles.

Claim 6. (Original) A compound as described in claim 1, 2, or 5, which is in the form of crystals having the full XRD pattern of FIG. 5 characteristic peaks of angle of diffraction (20), as measured through powder x-ray diffractometry, at 7.2, 12.9, 17.3, 18.9, 19.8, 21.6, 26.8, and 30.5 (°).

Claim 7 (Currently Amended) A medicine containing, as an active ingredient, a compound as described in any one of claims 1 to 6 claim 1.

Claims 8-15 (Cancelled).

Application No. 10/562,122 Reply to Office Action of May 1, 2008

Claim 16 (New) A medicine containing, as an active ingredient, a compound as described in claim 2.

Claim 17 (New) A medicine containing, as an active ingredient, a compound as described in claim 3.

Claim 18 (New) A medicine containing, as an active ingredient, a compound as described in claim 4.

Claim 19 (New) A medicine containing, as an active ingredient, a compound as described in claim 5.